Garland Capital Management Inc. lifted its holdings in Novartis AG (NYSE:NVS) by 0.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 54,940 shares of the company’s stock after purchasing an additional 475 shares during the period. Novartis accounts for approximately 3.6% of Garland Capital Management Inc.’s portfolio, making the stock its 14th biggest holding. Garland Capital Management Inc.’s holdings in Novartis were worth $5,017,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of NVS. Quadrant Capital Group LLC grew its position in Novartis by 18.7% during the second quarter. Quadrant Capital Group LLC now owns 22,071 shares of the company’s stock worth $2,002,000 after buying an additional 3,470 shares in the last quarter. Confluence Investment Management LLC grew its position in Novartis by 5.5% during the second quarter. Confluence Investment Management LLC now owns 230,583 shares of the company’s stock worth $21,055,000 after buying an additional 12,071 shares in the last quarter. Moody Lynn & Lieberson LLC grew its position in Novartis by 4.2% during the second quarter. Moody Lynn & Lieberson LLC now owns 4,298 shares of the company’s stock worth $392,000 after buying an additional 175 shares in the last quarter. Arden Trust Co acquired a new stake in Novartis during the second quarter worth about $2,347,000. Finally, Commerzbank Aktiengesellschaft FI grew its position in Novartis by 66.3% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 11,621 shares of the company’s stock worth $1,061,000 after buying an additional 4,631 shares in the last quarter. Institutional investors and hedge funds own 11.85% of the company’s stock.
NYSE NVS opened at $92.18 on Friday. The company has a quick ratio of 0.74, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $91.51. The firm has a market capitalization of $211.49 billion, a P/E ratio of 18.11, a price-to-earnings-growth ratio of 2.08 and a beta of 0.58. Novartis AG has a 1-year low of $71.33 and a 1-year high of $95.00.
A number of equities research analysts recently weighed in on NVS shares. Argus lifted their target price on Novartis to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. They noted that the move was a valuation call. Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Kepler Capital Markets downgraded Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Zacks Investment Research downgraded Novartis from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a report on Friday, July 19th. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a report on Friday, July 5th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $90.63.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Recommended Story: Is the QQQ ETF safe?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.